Dicot Pharma invites to a Q&A session on TO 6

Dicot Pharma's warrants of series TO 6 have a redemption period and can be exercised March 17-31. To answer any questions, a Q&A session in Swedish will take place via Zoom on Thursday, March 20 at 12.30 and will also be available for viewing afterwards. Questions can be asked online at the session or before via [email protected].

CEO Elin Trampe comments: "We want to enable our existing but also potential new warrant holders to ask questions live directly to the company. We will start with a short status update and then open up for questions."

To register to attend the live Q&A session, please go to

https://us02web.zoom.us/webinar/register/WN_kZrwRSWgT5eQur7vueiMIQ

Information on how to subscribe, use of proceeds, etc. is sent to both warrant and share holders registered in Sweden and should reach the recipients around March 19. Information is also available on the website https://www.dicotpharma.com/en/investor-relations/reports-and-issues/to-6-warrants/

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market. 

Dicot Pharma is listed on Nasdaq First North and has approximately 9,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.